Contact this trialFirst, we need to learn more about you.
Radioimmunotherapy
Astatine-211 for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Seattle, Washington
This trial gives cancer patients astatine-211, a radioactive substance, before their donor stem cell transplant. The hope is that the astatine will kill the cancer cells while having less of an effect on the healthy cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service